Literature DB >> 17666365

The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy.

David Pereg1, Gideon Koren, Michael Lishner.   

Abstract

BACKGROUND AND OBJECTIVES: Lymphoma is the fourth most frequent malignancy diagnosed during pregnancy, occurring in approximately 1 over 6000 deliveries. DESIGN AND METHODS: Its occurrence may increase due to the current trend to postpone pregnancy until later in life and the evidence suggested high incidence of AIDS-related non-Hodgkin's lymphoma in developing countries. The relatively rare occurrence of pregnancy-associated lymphoma precludes the conduction of large, prospective studies to examine diagnostic, management and outcome issues.
RESULTS: Chemotherapy and radiotherapy during the first trimester are associated with increased risk of congenital malformations and this risk diminishes as pregnancy advances. In the vast majority of cases, when lymphoma is diagnosed during the first trimester, treatment with a standard chemotherapy regimen, following pregnancy termination should be recommended. In the rare patients at low risk, such as those with stage 1 Hodgkin's lymphoma or indolent non-Hodgkins lymphoma, therapy can be delayed until the end of the first trimester and of embryogenesis while keeping the patients under close observation. INTERPRETATION AND
CONCLUSIONS: When lymphoma is diagnosed during the second and third trimesters, evidence exists suggesting that full-dose chemotherapy can be administered safely without apparent increased risk of severe adverse fetal outcome.

Entities:  

Mesh:

Year:  2007        PMID: 17666365     DOI: 10.3324/haematol.11097

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  16 in total

Review 1.  Management of lymphoma in pregnancy.

Authors:  K Hodby; P A Fields
Journal:  Obstet Med       Date:  2009-05-22

2.  Pharmacokinetics of dacarbazine (DTIC) in pregnancy.

Authors:  Ira Kantrowitz-Gordon; Karen Hays; Olumide Kayode; Aditya R Kumar; Henry G Kaplan; Joel M Reid; Stephanie L Safgren; Matthew M Ames; Thomas R Easterling; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-05       Impact factor: 3.333

3.  Antenatal chemotherapy in a case of diffuse large B-cell lymphoma.

Authors:  Akhil Rajendra; Anup J Devasia; Nirmal Raj Francis; Vijay Prakash Turaka
Journal:  BMJ Case Rep       Date:  2018-01-31

4.  Up the Duff With Non-Hodgkin's Lymphoma: The Traumas and the Dilemmas.

Authors:  Sheeba Marwah; Harsha Shailesh Gaikwad; Ritin Mohindra; Manjula Sharma
Journal:  J Clin Diagn Res       Date:  2017-02-01

5.  Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth.

Authors:  Eun Ju Lee; Ki Hoon Ahn; Soon Cheol Hong; Eun Hee Lee; Yong Park; Byung Soo Kim
Journal:  Obstet Gynecol Sci       Date:  2014-11-20

Review 6.  Management of Hematologic Malignancies: Special Considerations in Pregnant Women.

Authors:  Odelia Amit; Merav Barzilai; Irit Avivi
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

7.  Bone lymphoma revealed by cruralgia during pregnancy: a case report.

Authors:  Ghita Sqalli Houssaini; Latifa Tahiri; Abdelhalim Ibrahimi; Siham Tizniti; Abdelmajid Elmrini; Taoufik Harzy
Journal:  Pan Afr Med J       Date:  2014-07-06

8.  Burkitt's lymphoma successfully treated in pregnancy.

Authors:  Alan Lúcio Alves Inácio Júnior; Beatriz Fernandes Rocha; Luís Fábio Barbosa Botelho
Journal:  Rev Bras Hematol Hemoter       Date:  2014-11-21

9.  [Difficulty of the management of acute leukemia during pregnancy in Morocco].

Authors:  Rajaa Tissir; Mouna Lamchahab; Mustapha Benhassou; Meryeme Quachouh; Mohammed Rachid; Said Benchakroun; Asmaa Quessar
Journal:  Pan Afr Med J       Date:  2012-09-05

Review 10.  The treatment of hematologic malignancies in pregnancy.

Authors:  C Vandenbriele; D Dierickx; F Amant; M Delforge
Journal:  Facts Views Vis Obgyn       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.